Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04021563




Registration number
NCT04021563
Ethics application status
Date submitted
9/07/2019
Date registered
16/07/2019
Date last updated
5/09/2021

Titles & IDs
Public title
The Safety, Tolerability, Pharmacokinetics(PK) of SR419 in Healthy Volunteers
Scientific title
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of SR419 in Healthy Volunteers
Secondary ID [1] 0 0
SR419-101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy Volunteers 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - SR419
Treatment: Drugs - Placebo

Experimental: SR419 - Ascending single and multiple doses of SR419 orally

Placebo Comparator: Placebo - Ascending single and multiple doses of placebo orally


Treatment: Drugs: SR419
Ascending single and multiple doses of SR419 orally

Treatment: Drugs: Placebo
Ascending single and multiple doses of placebo orally
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The frequency and severity of AEs in healthy volunteers adminstrated with single and repeated oral doses of SR419
Timepoint [1] 0 0
Up to Day14 for the safety follow up since Day1
Primary outcome [2] 0 0
Heart rate changes since baseline (categorized as normal; abnormal, not clinically significant; and abnormal, clinically significant)
Timepoint [2] 0 0
Up to Day14 for the safety follow up since Day1
Primary outcome [3] 0 0
PR interval changes since baseline (categorized as normal; abnormal, not clinically significant; and abnormal, clinically significant)
Timepoint [3] 0 0
Up to Day14 for the safety follow up since Day1
Primary outcome [4] 0 0
QRS duration changes since baseline (categorized as normal; abnormal, not clinically significant; and abnormal, clinically significant)
Timepoint [4] 0 0
Up to Day14 for the safety follow up since Day1
Primary outcome [5] 0 0
QT interval changes since baseline (categorized as normal; abnormal, not clinically significant; and abnormal, clinically significant)
Timepoint [5] 0 0
Up to Day14 for the safety follow up since Day1
Primary outcome [6] 0 0
QTcF changes since baseline (categorized as normal; abnormal, not clinically significant; and abnormal, clinically significant)
Timepoint [6] 0 0
Up to Day14 for the safety follow up since Day1
Primary outcome [7] 0 0
Systolic blood pressure changes since baseline
Timepoint [7] 0 0
Up to Day14 for the safety follow up since Day1
Primary outcome [8] 0 0
Diastolic blood pressure changes since baseline
Timepoint [8] 0 0
Up to Day14 for the safety follow up since Day1
Primary outcome [9] 0 0
Pulse rate changes since baseline
Timepoint [9] 0 0
Up to Day14 for the safety follow up since Day1
Primary outcome [10] 0 0
Respiratory rate changes since baseline
Timepoint [10] 0 0
Up to Day14 for the safety follow up since Day1
Primary outcome [11] 0 0
Oral temperature changes since baseline
Timepoint [11] 0 0
Up to Day14 for the safety follow up since Day1
Secondary outcome [1] 0 0
Cmax
Timepoint [1] 0 0
Up to Day 9
Secondary outcome [2] 0 0
Tmax
Timepoint [2] 0 0
Up to Day 9
Secondary outcome [3] 0 0
AUC
Timepoint [3] 0 0
Up to Day 9
Secondary outcome [4] 0 0
CL/F
Timepoint [4] 0 0
Up to Day 9
Secondary outcome [5] 0 0
t1/2
Timepoint [5] 0 0
Up to Day 9
Secondary outcome [6] 0 0
R0
Timepoint [6] 0 0
Up to Day 9
Secondary outcome [7] 0 0
Ae
Timepoint [7] 0 0
Up to Day 9
Secondary outcome [8] 0 0
CLr
Timepoint [8] 0 0
Up to Day 9

Eligibility
Key inclusion criteria
1. Healthy males and females who are 18 to 64 years of age inclusive are eligible for
Parts A and B.

2. Healthy males and females who are 65 to 80 years of age inclusive, defined as elderly
subjects in this study, are eligible for Part C only.

3. Average of triplicate QTcF values must be < 450 msec for males and < 470 msec for
females at Screening and Day -1.

4. Bodyweight > 50 kg (110 pounds) and body mass index (BMI) between 18 and 30 kg/m2

5. The participants must agree to use contraception methods (outlined in Appendix 1)

6. Capable of giving written informed consent, which includes compliance with the
requirements and restrictions listed in the consent form.

7. Male subjects must agree to use contraception methods (outlined in Appendix 1) if they
have a female partner of childbearing potential and must agree not to donate sperm.
This criterion must be followed from the time of the first dose of investigational
medicinal product (IMP) until at least 90 days after the last dose of IMP. This
requirement does not apply to subjects in a same-sex relationship and female partners
of non-childbearing potential.

8. A female subject is eligible to participate if she is:

a. of non-childbearing potential, defined as: i. Pre- menopausal females with a
documented tubal ligation, tubal occlusion procedure followed by a hysterosalpingogram
that confirmed bilateral tubal occlusion, bilateral salpingectomy, hysterectomy or
other documented medical conditions which cause infertility and are considered to be
of non-childbearing potential; ii. Postmenopausal defined as 12 months of spontaneous
amenorrhea (in questionable cases a blood sample with follicle stimulating hormone
[FSH] >40 mIU/mL is confirmatory). b. of childbearing potential, and one of the
following applies: i. Is willing to practice true abstinent from the time of consent
until at least 30 days after the last dose of IMP or 5× half-lives of the IMP,
whichever is longer; ii. Agrees to comply with the protocol defined contraception
requirements outlined in Appendix 1 from at least 1 month before her first dose of
IMP, and until at least 30 days after her last dose of IMP or 5× half-lives of the
IMP, whichever is longer.

9. Capable of giving written informed consent, which includes compliance with the
requirements and restrictions listed in the consent form.
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Clinically significant history of central nervous system (CNS) disease, such as
cognitive disorder and seizures. History of non-clinically significant mild anxiety
(related to social stressors) or situational sleep disturbance > 6 months ago could be
enrolled under the discretion of the Investigators.

2. Known history of renal dysfunction or creatinine clearance < 90 mL/min or = 150 mL/min
(calculated using the Cockcroft-Gault formula) at Screening.

3. Current or chronic history of liver disease or known hepatic or biliary abnormalities
(with the exception of Gilbert's syndrome [indirect bilirubin < 5 mg/dL with no other
clinically significant abnormalities seen] or asymptomatic gallstones).

4. History of regular alcohol consumption within 6 months of screening defined as: an
average weekly intake of >21 units for males or >14 units for females. One unit is
equivalent to 8 g of alcohol: a half-pint (~285 mL) of beer, 1 glass (125 mL) of wine
or 1 measure (25 mL) of spirits.

5. History of significant drug abuse within one year of screening or use of soft drugs
(such as marijuana) within 3 months prior to screening or hard drugs (such as cocaine,
methamphetamine, crack) within 1 year prior to screening.

6. History of sensitivity to any of the IMPs, or components thereof or a history of drug
or other allergy that, in the opinion of the Investigator or Medical Monitor,
contraindicates participation.

7. History of asthma (excluding resolved childhood asthma), anaphylaxis or anaphylactoid
reactions, severe allergic responses.

8. History of hypercoagulable state or history of thrombosis.

9. A history of biliary tract disease including a history of liver disease with elevated
liver function tests of known or unknown etiology (with the exception of Gilbert's
syndrome).

10. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
result within 3 months of screening.

11. Use of tobacco- or nicotine-containing products:

1. Parts A and B: positive urinary cotinine test at Screening or Day -1 or history
of regular use of tobacco- or nicotine-containing products (more than 4 products
per month within 6 months prior to screening) or unwilling to refrain from use of
such products from Screening until completion of the final study visit;

2. Part C: positive urinary cotinine test at Screening or Day -1 or history of
regular use of tobacco- or nicotine-containing products (more than 4 products per
month within 6 months prior to screening) or unwilling to give up these products
from Screening until discharge from the study unit.

12. A positive pre-study drug/alcohol result at Screening or Day -1.

13. A positive test for human immunodeficiency virus (HIV) antibody.

14. Donation or lost in excess of 500 mL of blood within 56 days of Day 1 or donation of
plasma within 14 days of Day 1.

15. The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the first dosing day in the current
study: 30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer).

16. Exposure to more than four new chemical entities within 12 months prior to the first
dosing day.

17. Use of medication other than topical products without significant systemic absorption:

1. prescription within 14 days and over-the-counter (OTC) medications within 7 days,
or 5× half-lives (whichever is longer) prior to the first dose of IMP, with the
exception of the occasional use of paracetamol (up to 2 g daily)

2. natural health products (e.g. food supplements and herbal supplements) within 7
days prior to the first dose of IMP;

3. a depot injection or an implant of any drug within 3 months prior to the first
dose of IMP.

4. vaccine within 1 month prior to the first dose of IMP.

18. Unable to refrain from consumption of Seville oranges, grapefruit or grapefruit juice
within 7 days prior to the first dose of IMP until the Safety Follow-up visit.

19. A positive pre-study pregnancy test at Screening or Day -1.

20. Breast-feeding and/or lactating subject.

21. Any reason which, in the opinion of the Investigator, would prevent the subject from
participating in the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/07/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
10/12/2019
Sample size
Target
Accrual to date
Final
64
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Linear Clinical Research - Perth
Recruitment postcode(s) [1] 0 0
- Perth

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
SIMR (Australia) Biotech Pty Ltd.
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Syneos Health
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study is to evaluate the safety, tolerability, PK of SR419 in healthy volunteers.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04021563
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Dr.Hatchuel
Address 0 0
Linear Clinical Research
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04021563